# A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years

> **NCT06225115** · PHASE1 · COMPLETED · sponsor: **Kynexis B.V.** · enrollment: 72 (actual)

## Conditions studied

- Cognitive Dysfunction
- Schizophrenia

## Interventions

- **DRUG:** KYN-5356
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT06225115
- **Lead sponsor:** Kynexis B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-21
- **Primary completion:** 2024-10-07
- **Final completion:** 2024-10-07
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2024-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06225115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06225115, "A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06225115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*